Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
Linda Gail BekkerMoupali DasQuarraisha Abdool KarimKhatija AhmedJoanne BattingWilliam BrumskineKatherine GillIshana HarkooManjeetha JaggernathGodfrey KigoziNoah KiwanukaPhilip KotzeLimakatso LebinaCheryl E LouwMoelo MalahlehaMmatsie ManentsaLeila E MansoorDhayendre MoodleyVimla NaickerLogashvari NaidooMegeshinee NaidooGonasagrie NairNkosiphile NdlovuThesla Palanee-PhillipsRavindre PanchiaSaresha PillayDisebo PotloanePearl SelepeNishanta SinghYashna SinghElizabeth SpoonerAmy M WardZwelethu ZwaneRamin EbrahimiYang ZhaoAlexander KintuChris DeatonChristoph C CarterJared M BaetenFlavia Matovu Kiweewanull nullPublished in: The New England journal of medicine (2024)
No participants receiving twice-yearly lenacapavir acquired HIV infection. HIV incidence with lenacapavir was significantly lower than background HIV incidence and HIV incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 1 ClinicalTrials.gov number, NCT04994509.).